No connection

Search Results

BIAF vs MGRX

BIAF
bioAffinity Technologies, Inc.
BEARISH
Price
$1.35
Market Cap
$6.1M
Sector
Healthcare
AI Confidence
95%
MGRX
Mangoceuticals, Inc.
BEARISH
Price
$0.39
Market Cap
$6.7M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
BIAF
--
MGRX
--
Forward P/E
BIAF
-2.25
MGRX
--
P/B Ratio
BIAF
0.52
MGRX
0.35
P/S Ratio
BIAF
0.9
MGRX
14.63
EV/EBITDA
BIAF
0.09
MGRX
-0.36

Profitability

Gross Margin
BIAF
27.86%
MGRX
54.91%
Operating Margin
BIAF
-158.56%
MGRX
-1576.4%
Profit Margin
BIAF
-217.5%
MGRX
0.0%
ROE
BIAF
-245.18%
MGRX
-141.66%
ROA
BIAF
-71.71%
MGRX
-69.91%

Growth

Revenue Growth
BIAF
-38.5%
MGRX
-10.3%
Earnings Growth
BIAF
--
MGRX
--

Financial Health

Debt/Equity
BIAF
0.08
MGRX
0.02
Current Ratio
BIAF
3.65
MGRX
1.74
Quick Ratio
BIAF
3.44
MGRX
1.67

Dividends

Dividend Yield
BIAF
--
MGRX
--
Payout Ratio
BIAF
0.0%
MGRX
0.0%

AI Verdict

BIAF BEARISH

The Advanced Deterministic Scorecard reveals a critically weak financial profile with a Piotroski F-Score of just 1/9, indicating severe operational and financial distress. Despite a seemingly healthy Current Ratio of 3.65 and low Debt/Equity of 0.08, the company is deeply unprofitable, with a Profit Margin of -217.50% and ROE of -245.18%. Revenue has collapsed by 38.5% year-over-year, and the stock has lost nearly all value over the past five years, down 99.5%. While the recent 1-month price increase of +9.8% may suggest speculative momentum, fundamentals remain abysmal, and the lack of analyst coverage or target prices underscores minimal market confidence.

Strengths
Strong liquidity position with Current Ratio of 3.65 and Quick Ratio of 3.44
Low leverage with Debt/Equity ratio of only 0.08
Positive gross margin of 27.86%, indicating some pricing power or cost control at production level
Risks
Critically low Piotroski F-Score of 1/9 signals high risk of financial failure
Massive and sustained profitability deficits: Operating Margin of -158.56%, ROA of -71.71%
Revenue declining sharply by 38.5% year-over-year, indicating deteriorating business fundamentals
MGRX BEARISH

MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.

Strengths
Low Debt/Equity ratio (0.02)
Positive Gross Margin (54.91%)
Current Ratio of 1.74 suggests short-term liquidity
Risks
Extreme operating losses (-1576.40% operating margin)
Negative revenue growth both YoY and Q/Q
Severe long-term price decay (-99.3% over 5 years)

Compare Another Pair

BIAF vs MGRX: Head-to-Head Comparison

This page compares bioAffinity Technologies, Inc. (BIAF) and Mangoceuticals, Inc. (MGRX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile